Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Inspire Medical Systems ( (INSP) ).
Inspire Medical Systems reported a 25% increase in revenue for the fourth quarter of 2024, reaching $239.7 million, and a 28% increase for the full year, totaling $802.8 million. Net income for the quarter was $35.2 million, with diluted net income per share rising by 135%. The company activated 72 new U.S. centers, bringing the total to 1,435, and created 12 new U.S. sales territories. Looking ahead, Inspire reaffirmed its 2025 revenue guidance, anticipating growth of 17% to 19%, with a revenue range of $940 million to $955 million and introduced diluted earnings per share guidance of $2.10 to $2.20. The company aims to continue its strong performance with the full launch of Inspire V and other strategic initiatives.
More about Inspire Medical Systems
Inspire Medical Systems, Inc. is a medical technology company specializing in developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea. They offer the proprietary Inspire therapy, which is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology providing a safe and effective treatment for moderate to severe obstructive sleep apnea.
YTD Price Performance: -3.72%
Average Trading Volume: 518,196
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.46B
Find detailed analytics on INSP stock on TipRanks’ Stock Analysis page.
